Amaris first to offer two energy levels

Article

Amaris is the first refractive laser in the world to offer two separate energy levels for optimal corneal smoothing, according to an announcement from Schwind, the laser's manufacturer.

Amaris is the first refractive laser in the world to offer two separate energy levels for optimal corneal smoothing, according to an announcement made by Schwind, the laser's manufacturer.

The laser, which has a 500 Hz pulse frequency, includes a unique "Automatic Fluence Level Adjustment" feature, enabling the laser to switch between high and low levels of fluence to provide the most appropriate energy level for each cornea. Approximately 80% of the ablation is performed at high fluence; for the remaining 20% of the procedure, the laser automatically lowers the fluence value to whatever level is most appropriate. Dual fluence levels are also able to treat subjective refractions and higher order aberrations.

Schwind believes that this combination of high and low fluence values and pulse frequencies offers optimum results for patients, as well as increasing the lifetime of the equipment.

The images show ablation variations: please click on an image to enlarge.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared exciting new research with the Eye Care Network during the Association for Research in Vision and Ophthalmology (ARVO) meeting on the subject of Leber hereditary optic neuropathy (LHON).
At this year's Association for Research in Vision and Ophthalmology (ARVO) meeting in Salt Lake City, Utah, Nitish Mehta, MD, shared highlights from his research documenting real-world results of aflibercept 8 mg for patients with diabetic macular oedema.
ARVO 2025: Anat Loewenstein, MD, shares data from herself and her colleagues on meeting needs of patients with diabetic retinopathy
At the American Society of Cataract and Refractive Surgeons annual meeting, Sheng Lim, MD, FRCOphth discusses the benefit of endoscopic cyclophotocoagulation for patients with primary open angle glaucoma and cataracts in the CONCEPT study
A photo of Seville, Spain, with the Congress on Controversies in Ophthalmology logo superimposed on it. Image credit: ©francovolpato – stock.adobe.com; logo courtesy COPHy
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center, discusses the Congress on Controversies in Ophthalmology (COPHy)
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
Sarah M. Thomasy, DVM, PhD, DACVO, a veterinary ophthalmologist at UC Davis, talks about how her research at the Glaucoma 360 symposium
I. Paul Singh, MD, an anterior segment and glaucoma specialist, discusses the Glaucoma 360 conference, where he participated in a panel discussion on the use of artificial intelligence (AI) in glaucoma care.
Charles Wykoff, MD, PhD, discusses his Floretina ICOOR presentation topic, retinal non-perfusion in diabetic retinopathy, with David Hutton, editor of Ophthalmology Times
© 2025 MJH Life Sciences

All rights reserved.